Key result
The ACE-I/I homozygote genotype was associated with a lower likelihood of Alzheimer's disease compared to I/D and D/D genotypes (OR 0.601; 95% CI 0.372-0.969; P=0.037).
Why the study?
Is the ACE gene insertion/deletion polymorphism associated with Alzheimer's disease and plasma ACE protein levels in a Taiwanese population?
Case-Control (n=394)
Is the ACE gene insertion/deletion polymorphism associated with Alzheimer's disease and plasma ACE protein levels in a Taiwanese population?
The ACE-I/I genotype is associated with lower plasma ACE levels and a reduced risk of Alzheimer's disease in the Taiwanese population.
ACE I/I genotype should not yet inform Alzheimer's risk assessment; leaves open a protective association needing prospective confirmation.
BACKGROUND: angiotensin-converting enzyme (ACE) gene insertion/deletion (indel) polymorphism is considered a biomarker for Alzheimer's disease (AD). However, the associations of ACE gene and protein level to AD are undetermined among Taiwanese. METHODS: this study investigated 257 Taiwanese cases with AD and 137 ethnically matched controls using ACE gene indel genotype association methods with logistic regression adjusted for other variables. Besides, 65 out of 257 AD patients, 11 with D/D genotype, 28 with I/I genotype and 26 with I/D genotype were recruited. Their plasma ACE protein levels were measured by enzyme-linked immuno-sorbent assay and compared for their corresponding ACE gene indel polymorphism. RESULTS: patients with ACE-I/I homozygote were less likely to be associated with AD, compared with both I/D and D/D (OR: 0.601; 95% CI: 0.372-0.969; P = 0.037), or only I/D genotype (OR: 0.584; 95% CI: 0.349-0.976; P = 0.040). There were significantly different plasma ACE protein levels among these three different genotype groups (P = 0.023). The I/I genotype group had significantly lower ACE plasma levels [114.79 ± 31.32 ng/ml (mean ± SD)], compared with D/D (164.07 ± 86.36 ng/ml; P = 0.010), but not I/D (141.45 ± 51.50 ng/ml; P = 0.064). CONCLUSION: ACE-I/I homozygote corresponds to lower plasma ACE protein level and it is independently but less likely to be associated with AD. These findings signal the importance of ACE indel polymorphisms to their corresponding protein levels and to AD.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2011) conducted a case-control in Alzheimer's disease (n=394). ACE-I/I homozygote genotype vs. I/D and D/D genotypes was evaluated on Association with Alzheimer's disease (OR 0.601, 95% CI 0.372-0.969, p=0.037). The ACE-I/I homozygote genotype was associated with a lower likelihood of Alzheimer's disease compared to I/D and D/D genotypes (OR 0.601; 95% CI 0.372-0.969; P=0.037).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: